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Abstract
Traditionally, immune priming followed by an antigen-boost is utilized for vaccine-induced protective
immunity and maintaining long-term immunity often requires repeated exposure to antigen. Here, a novel
single dose vaccination platform designed with gonadotropin releasing hormone multiple antigenic peptide as
a model antigen is shown.
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Traditionally, immune priming followed by an antigen-boost is
utilized for vaccine-induced protective immunity and maintaining
long-term immunity often requires repeated exposure to antigen.
Here, a novel single dose vaccination platform designed with gona-
dotropin releasing hormone multiple antigenic peptide as a model
antigen is shown. Initially a soluble component will prime the
immune system followed by vaccine release from a biodegradable
polyanhydride (PA) copolymer rod of 1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy) hexane
(CPH) for immune boosting (Appendix A) [1]. A second PA-based
vaccine depot is enclosed within an implant of biocompatible high
molecular weight polyethylene, which limits PA degradation and
antigen release to a single surface, significantly extending the
release kinetics (Supplemental Table). Collagen is used to generate
an immunodiffusion barrier [2] over the PA wherein antigen-
antibody complex formation can occur for an immune feedback
design (Fig. 1). Therefore, antigen release is impeded, theoretically,
by high antibody titers. The cap of the implant is a hydrophilic poly
(vinylidene fluoride) membrane with 0.65-mm pores that allows
flow of proteins into and out of the implant, while excluding leuko-
cytes. Thus, this device enables vaccine priming, boost and long
term maintenance with a single administration of antigen.
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Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2017.11.
067.
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Fig. 1. Schematic of 3 stage single injection vaccine delivery device (top) with soluble priming dose, polyanhydride (PA) depot boosting dose, and implant for maintenance of
immunity. The lower left schematic illustrates the theoretical passive immunoregulation of vaccine release from the implant. The lower right is an image of the implant with
the PA depot that will be placed within.
R.G. Schaut et al. / Vaccine 36 (2018) 1024–1025 1025
